107. 若年性特発性関節炎 Juvenile idiopathic arthritis Clinical trials / Disease details
臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-004153-25-GB (EUCTR) | 10/12/2004 | 17/02/2005 | Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure. - rhGH in JIA | Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure. - rhGH in JIA | Growth retardation secondary to juvenile idiopathic arthritis | Trade Name: Norditropin SimpleXx 5mg/1.5ml Product Name: Norditropin SimpleXx INN or Proposed INN: Somatropin Other descriptive name: Growth Hormone | Royal Hospital For Sick Children, Yorkhill Division | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 2 | NCT00420251 (ClinicalTrials.gov) | March 1996 | 9/1/2007 | Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis | Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development | Juvenile Idiopathic Arthritis;Still Disease, Juvenile-Onset | Drug: Genotropin | Ludwig-Maximilians - University of Munich | Pfizer | Completed | 4 Years | 14 Years | Both | 50 | Phase 3 | Germany |
| 3 | EUCTR2014-004105-32-Outside-EU/EEA (EUCTR) | 01/04/2015 | Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With Chronic Juvenile Arthritis (CJA) Treated by Corticosteroid Therapy | Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor (Genotonorm) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-Term Corticosteroid Therapy. Extension of the Study Beyond Three Years. | Juvenile idiopathic arthritis (JIA);Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: Genotropin INN or Proposed INN: Somatropin Other descriptive name: SOMATROPIN | Pfizer Inc | NULL | NA | Female: yes Male: yes | 21 | France | ||||
| 4 | EUCTR2014-004104-30-Outside-EU/EEA (EUCTR) | 01/04/2015 | Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety | Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety | Juvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS);Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: Genotropin INN or Proposed INN: Somatropin Other descriptive name: SOMATROPIN | Pharmacia & Upjohn S.A. | NULL | NA | Female: yes Male: yes | 30 | France |